Marketing en publicaire copywriting voor zelfstandigen en kmo s
Octreotide
1
Reactions 1425 - 27 Oct 2012 S Octreotide Hepatitis in a child: case report A girl [age at reaction onset not clearly stated] developed hepatitis during treatment with octreotide for congenital hyperinsulinism. The girl started bolus SC octreotide 5 µg/kg/day on day 23 of life, after a partial response to diazoxide. Despite dose escalation to a maximum of 20 µg/kg/day, her hypoglycaemia recurred, and she underwent subtotal pancreatectomy at 11 months of age. When hypoglycaemia recurred again, octreotide was restarted, with escalation to 20 µg/kg/day, and further escalation to 30 µg/kg/day by subcutaneous continuous pump. Her ALT levels transiently increased after an episode of candida central line sepsis. Subsequently, her ALT levels increased as her octreotide dose increased, with a peak of 1061 U/L [duration of treatment to reaction onset not clearly stated]. Octreotide was stopped for 2 weeks, and the girl received glucagon and glucose. Her ALT levels decreased, but increased again after octreotide was restarted. Octreotide was withdrawn and she underwent a second near-total pancreatectomy. Her ALT levels normalised, and remained normal during follow-up. Author comment: "In this patient, the association of serum ALT levels increasing temporally with increasing doses of Octreotide, the exclusion of common causes of hepatitis and subsequent normalisation of ALT following complete cessation of the drug strongly suggest that hepatitis was induced by Octreotide." Avatapalle B, et al. Drug-induced hepatitis following use of octreotide for long- term treatment of congenital hyperinsulinism. BMJ Case Reports 2012: [3 pages], 3 Jul 2012. Available from: URL: http://dx.doi.org/10.1136/bcr-2012-006271 - United Kingdom 803079099 1 Reactions 27 Oct 2012 No. 1425 0114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 1425 - 27 Oct 2012
SOctreotide
Hepatitis in a child: case reportA girl [age at reaction onset not clearly stated] developed
hepatitis during treatment with octreotide for congenitalhyperinsulinism.
The girl started bolus SC octreotide 5 µg/kg/day onday 23 of life, after a partial response to diazoxide. Despitedose escalation to a maximum of 20 µg/kg/day, herhypoglycaemia recurred, and she underwent subtotalpancreatectomy at 11 months of age. When hypoglycaemiarecurred again, octreotide was restarted, with escalation to20 µg/kg/day, and further escalation to 30 µg/kg/day bysubcutaneous continuous pump. Her ALT levels transientlyincreased after an episode of candida central line sepsis.Subsequently, her ALT levels increased as her octreotidedose increased, with a peak of 1061 U/L [duration oftreatment to reaction onset not clearly stated].
Octreotide was stopped for 2 weeks, and the girlreceived glucagon and glucose. Her ALT levels decreased,but increased again after octreotide was restarted.Octreotide was withdrawn and she underwent a secondnear-total pancreatectomy. Her ALT levels normalised, andremained normal during follow-up.
Author comment: "In this patient, the association ofserum ALT levels increasing temporally with increasing dosesof Octreotide, the exclusion of common causes of hepatitisand subsequent normalisation of ALT following completecessation of the drug strongly suggest that hepatitis wasinduced by Octreotide."Avatapalle B, et al. Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism. BMJ Case Reports 2012: [3 pages],3 Jul 2012. Available from: URL: http://dx.doi.org/10.1136/bcr-2012-006271 -United Kingdom 803079099
1
Reactions 27 Oct 2012 No. 14250114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
